Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 to 75 years old.~* Sex: both males and females.~* Karnofsky performance status (KPS) \>60.~* Histological biopsy confirming squamous cell carcinoma of the oral cavity (tongue, gingiva, buccal mucosa, floor of mouth, palate, and retromolar region).~* Clinical stage III/IVA (T1-2, N2, M0 or T3-4, N2, M0, UICC\[International Union Against Cancer \]2002) with resectable lesions.~* Adequate hematologic function: white blood cell \>3,000/mm3, hemoglobin\>8g/L, platelet count\>80,000/mm3.~* Hepatic function: ALAT(alanine aminotransferase )/ASAT(aspartate transaminase ) \<2.5 times the upper limit of normal (ULN), bilirubin \<1.5 times ULN.~* Renal function: serum creatinine \<1.5 times ULN.~* Written informed consent~Exclusion Criteria:~* Evidence of distant metastatic disease and other cancers.~* Surgical procedure of the primary tumors or lymph nodes (except diagnostic biopsy).~* Previous radiotherapy or chemotherapy.~* Other previous malignancies within 5 years.~* Can not tolerate the treatment protocol with systematic diseases such as history of severe pulmonary or cardiac diseases.~* Legal incapacity or limited legal capacity.~* Creatinine clearance \<30ml/min.~* Pregnancy (confirmed by serum or urine β-HCG) or lactation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TPF group (Type: EXPERIMENTAL): The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day
- Control group (Type: OTHER): The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).